Company / Total Assets
Royalty Pharma plc Total Assets History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Assets
$19.6B
FY2025
5-year range
$16.4B / $19.6B
FY2021-FY2025
Trend
+7.7%
vs FY2024
Sector context
#16 of 214
Health Care
What the data says
Among 214 Health Care companies, Royalty Pharma plc is in the top 7% for total assets. Improved from $16.4B to $19.6B over the past 2 years.
Based on SEC 10-K filings.
$19.6B in FY2025 with a 5-year CAGR of +4.1%. Top quartile in the Health Care sector.
Improved from $16.4B to $19.6B over the past 2 years.
Health Care sector context is included.
Total Assets over time
Growth rates
- 3-Year CAGR
- +5.3%
- 5-Year CAGR
- +4.1%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 214This company $19.6B Sector average $7.5B
▼
+162.7% above sector average
Key checks
Key Insights
- 5-year CAGR of +4.1%, indicating consistent growth.
- In FY2025, total assets increased 7.7% year-over-year.
- Ranks #16 out of 214 companies in the Health Care sector.
- Lowest total assets in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 0.91 (distress zone, below 1.8 threshold)
- Strong profit margin: 38.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $19.6B | +7.7% |
| FY2024 | $18.2B | +11.2% |
| FY2023 | $16.4B | -2.6% |
| FY2022 | $16.8B | -4.0% |
| FY2021 | $17.5B | +9.3% |
| FY2020 | $16.0B | +28.7% |
| FY2019 | $12.4B | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026